title: In vitro fertilization outcome according to age and follicle-stimulating hormone levels on cycle day 3.
abstract: OBJECTIVE
  In a retrospective study, the prognostic factors of in vitro fertilization outcome were studied in women of 39 years of age or older, with an elevated cycle day 3 follicle-stimulating hormone (FSH) level.
  
  
  METHODS
  Ovarian stimulation was achieved with a combination of gonadotropin-releasing hormone agonist/human menopausal gonadotropin in a short protocol. All patients underwent FSH dosage on cycle day 3 prior to stimulation. The pregnancy rate was studied according to age, FSH levels, and stimulation parameters.
  
  
  RESULTS
  There was a negative correlation between day 3 FSH levels and the number of ovocytes retrieved. Cycles canceled because of the absence of ovarian response had a significantly higher mean FSH value (18.2 mlU/ml) than cycles ending in ovocyte retrieval (14.6 mlU/ml). Patients with three or more growing follicles during stimulation achieved a significantly higher pregnancy rate per egg retrieval (16%) compared to patients with fewer than three growing follicles (6%). Eighty percent of those pregnancies were obtained during the first two IVF cycles. Even with an elevated FSH level, some patients developed three or more follicles after stimulation. In such cases, the number of embryos available for transfer was the only significant limiting factor to achieving pregnancy.
  
  
  CONCLUSIONS
  As our results suggest, there is a discrepancy between biological and chronological ovarian age. In patients with an elevated cycle day 3 FSH level and over 40 years of age, alternatives to fertility treatments (ovum donation, adoption, or no treatment) should not be considered as first choices. Indeed, even with elevated FSH levels, a 16% pregnancy rate per egg retrieval may be obtained if three or more growing follicles can be seen during ovarian stimulation. However, in the presence of fewer than three growing follicles during ovarian stimulation, the patient should be informed about the discouraging prognosis of the running cycle.
authors.affiliation: Catholic University of Louvain, Faculty of Medicine, Department of Gynecology, St Luc's University Hospital, Brussels, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: Bassil
authors.forename: P A
authors.initials: PA
authors.lastname: Godin
authors.forename: S
authors.initials: S
authors.lastname: Gillerot
authors.forename: J C
authors.initials: JC
authors.lastname: Verougstraete
authors.forename: J
authors.initials: J
authors.lastname: Donnez
mesh_terms: D000328:Adult; D000375:Aging / Q000502:physiology*; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006801:Humans; D008423:Maternal Age; D008596:Menotropins / Q000008:administration & dosage; D009865:Oocytes / Q000502:physiology; D010062:Ovulation Induction; D011247:Pregnancy; D012189:Retrospective Studies
chemical_list: D008596:Menotropins; D005640:Follicle Stimulating Hormone